Insys Therapeutics, Inc. is on the Cruelty Free Investing use of animals list because they use animals for drug testing and clinical trials.
The company stated in the following report that they conduct pre-clinical trials of their drugs on animals.
These may include artificial membranes or human skin models or in vivo animal models as appropriate. (Page 10) Read the full document
Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue. The Company markets Subsys through its field sales force focused on supportive care physicians in the United States. Subsys delivers a liquid fentanyl formulation in approximately 100, 200, 400, 600, 800, 1,200 and 1,600 micrograms (mcg) dosages. The Company’s lead dronabinol product candidate is Syndros, which is under review for approval by the Food and Drug Administration. In addition, the Company is evaluating sublingual spray, inhaled and intravenous formulations of dronabinol in preclinical studies. [Source: GoogleFinance]
Company Website: http://www.insysrx.com